Company / Capital Expenditures
Rein Therapeutics, Inc. Capital Expenditures History
FY2017-FY2022 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$157.0K
FY2022
5-year range
$5.0K / $157.0K
FY2018-FY2022
Trend
+3040.0%
vs FY2021
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Capital Expenditures changed +3040% YoY in FY2022, a notable deviation from the 5-year average annual change of +1183%.
Based on SEC 10-K filings.
$157,000 in FY2022 with a 5-year CAGR of +10.8%.
Improved from $151,000 to $157,000 over the past 2 years.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -67.1%
- 5-Year CAGR
- +10.8%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +10.8%, indicating consistent growth.
- In FY2022, capital expenditures increased 3040.0% year-over-year.
- Peak capital expenditures was recorded in FY2019.
- Lowest capital expenditures in the period was in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -9.18 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | $157.0K | +3040.0% |
| FY2021 | $5.0K | -96.7% |
| FY2020 | $151.0K | -96.6% |
| FY2019 | $4.4M | +3014.8% |
| FY2018 | $142.0K | +51.1% |
| FY2017 | $94.0K | - |
As of FY2022 · SEC 10-K · Updated Jun 28, 2026